Your session is about to expire
← Back to Search
Unknown
A Study to Assess the Safety, Tolerability and Drug Levels of BMS-986172 in Healthy and Obese Participants, Including an Assessment of the Effects of Food on BMS-986172 Absorption
Phase 1
Waitlist Available
Research Sponsored by Bristol-Myers Squibb
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 28 days
Summary
This trial is testing a new drug called BMS-986172 to see if it is safe, how well people tolerate it, and how food affects its absorption. The study likely involves healthy volunteers or a general population.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 28 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 28 days
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Incidence of clinically significant changes in ECG parameters: QTcF
Trial Design
4Treatment groups
Experimental Treatment
Group I: Part D: FE/BAExperimental Treatment1 Intervention
FE/BA = Food Effect/Relative Bioavailability
Group II: Part C: JMADExperimental Treatment2 Interventions
JMAD= Japanese Multiple Ascending Dose
Group III: Part B: MADExperimental Treatment2 Interventions
MAD = Multiple Ascending Dose
Group IV: Part A: SADExperimental Treatment2 Interventions
SAD = Single Ascending Dose
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
BMS-986172
2021
Completed Phase 1
~40
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Bristol-Myers SquibbLead Sponsor
2,696 Previous Clinical Trials
4,099,031 Total Patients Enrolled